TY - JOUR
T1 - Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma
AU - Castagna, L
AU - Bramanti, S
AU - Devillier, R
AU - Sarina, B
AU - Crocchiolo, R
AU - Furst, S
AU - El-Cheikh, J
AU - Granata, A
AU - Faucher, C
AU - Harbi, S
AU - Morabito, L
AU - Mariotti, J
AU - Puvinathan, S
AU - Weiller, P J
AU - Chabannon, C
AU - Mokart, D
AU - Carlo-Stella, C
AU - Bouabdallah, R
AU - Santoro, A
AU - Blaise, D
PY - 2017/5
Y1 - 2017/5
N2 - We investigated the use of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in the treatment of advanced Hodgkin lymphoma (HL). Sixty-two consecutive HL patients underwent haplo-HSCT. Unmanipulated stem cells and post-transplant cyclophosphamide were given to all patients as GVHD prophylaxis. At 100 days, the cumulative incidence of grades 2-3 and grades 3-4 acute GVHD was 23% and 4%, respectively. The chronic GVHD (cGVHD) cumulative incidence was 16%, with one patient experiencing severe cGVHD. The 3-year OS, PFS, relapse rates and 1-year non-relapse mortality (NRM) were 63%, 59%, 21% and 20%, respectively. Uncontrolled disease status and high hematopoietic cell transplantation comorbidity index (HCT-CI) were associated with lower OS, whereas PBSC was an independent protective factor. Uncontrolled disease and HCT-CI >2 was predictive for NRM. Finally, disease status other than CR was predictive of relapse. In conclusion, haplo-HSCT is a valid treatment in advanced HL, offering excellent rates of survival and acceptable toxicities.
AB - We investigated the use of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in the treatment of advanced Hodgkin lymphoma (HL). Sixty-two consecutive HL patients underwent haplo-HSCT. Unmanipulated stem cells and post-transplant cyclophosphamide were given to all patients as GVHD prophylaxis. At 100 days, the cumulative incidence of grades 2-3 and grades 3-4 acute GVHD was 23% and 4%, respectively. The chronic GVHD (cGVHD) cumulative incidence was 16%, with one patient experiencing severe cGVHD. The 3-year OS, PFS, relapse rates and 1-year non-relapse mortality (NRM) were 63%, 59%, 21% and 20%, respectively. Uncontrolled disease status and high hematopoietic cell transplantation comorbidity index (HCT-CI) were associated with lower OS, whereas PBSC was an independent protective factor. Uncontrolled disease and HCT-CI >2 was predictive for NRM. Finally, disease status other than CR was predictive of relapse. In conclusion, haplo-HSCT is a valid treatment in advanced HL, offering excellent rates of survival and acceptable toxicities.
KW - Journal Article
U2 - 10.1038/bmt.2016.348
DO - 10.1038/bmt.2016.348
M3 - Article
C2 - 28092347
SN - 0268-3369
VL - 52
SP - 683
EP - 688
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 5
ER -